About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA). For additional information, please see the “About Access to Information Requests” webpage.
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 10261 record(s)
Req # A-2022-001559
Internal correspondence related to the Minister of Health‘s letter to provincial and territorial health ministers concerning patients being charged for medically necessary care. Related to the drafting of the letter, requests for information related to its contents, and discussions of when to send it. Between the dates of February 6, 2023 and March 10, 2023.Organization: Health Canada
February 2024
Req # A-2022-001649
Advise whether this desmopressin Abbreviated New Drug Submission (ANDS), which was accepted into review on or after March 1, 2022, but before December 1, 2022, has: received a Notice of Deficiency (NOD); received a Notice of Non-Compliance (NON); received a NOD-Withdrawal (NOD-W); received a NON-Withdrawal (NON-W); or is on Patent Hold. If this desmopressin ANDS has received any of the notices listed above, or if it was put on Patent Hold, advise of the month and year that the notice/hold was issued; and provide a copy of the correspondence.Organization: Health Canada
February 2024
Req # A-2023-000171
The Minister’s meeting records in 2022, 2023 with drug companies and/or trade associations which mention drug pricing and/or the Patented Medicine Prices Review Board (PMPRB). Provide 2022, 2023 records prepared for the Minister on PMPRB proposed drug lowering plans and challenges to that plan. Provide 2023 response to PMPRB members resignations and to expert health professionals concerned about the Minister’s pausing and intervening on the PMPRB plans.Organization: Health Canada
February 2024
Req # A-2023-000268
Module 5.2 (Tabular Listing of all Clinical Studies) for pms-Iron Sucrose that received a Notice of Compliance on 30 July 2020. Drug Identification Number (DIN) 02502917.Organization: Health Canada
February 2024
Req # A-2023-000395
The clinical trails for the premarket approval of the Selective Serotonin Reuptake Inhibitors (SNRI) antidepressant Effexor. The table of contents for all of those 12 paper volumes.Organization: Health Canada
February 2024
Req # A-2023-000426
PERIODIC SAFETY UPDATE REPORT #3 for COVID-19 VACCINE (nucleoside modified) (BNT162b2) to the European Medical Agency (EMA) on Aug 18, 2022 which covered the period from December 19, 2021 through June 18, 2022. Health Canada's and the Public Health Agency of Canada's research findings, reviews & results of the above-captioned document including any internal or external communications.Organization: Health Canada
February 2024
Req # A-2023-000432
Correspondence to and from the minister of Mental Health and Addictions concerning possible changes to the guidance on alcohol consumption in the time frame: January 1, 2022 to June 30 and July 1, 2022 to February 28, 2023.Organization: Health Canada
February 2024
Req # A-2023-000504
Acknowledgement letters from Health Canada to potential sponsor(s) regarding New Drug Submissions (NDS) currently under review for NURTEC ODT, including proposed indication.Organization: Health Canada
February 2024
Req # A-2023-000598
All notes made by the Health Canada employees who reviewed the Novavax Nuvaxovid COVID-19 vaccine, in relation to the review, that were made during the reviewal process of the drug. Date Range: January 1, 2020 to July 31, 2020.Organization: Health Canada
February 2024
Req # A-2023-000615
Information related to Tiotropium bromide monohydrate that Health Canada is currently reviewing. The product name and/or Drug Identification Number (DIN) of the reference product for which the Abbreviated New Drug Submission (ANDS) submission for Tiotropium bromide monohydrate medical ingredient was filed.Organization: Health Canada
February 2024